Genetic Engineering & Biotechnology News (GEN), in a feature article, outlines iBio’s (NYSE American:IBIO) transition from a contract development and manufacturing organization and cGMP biologics manufacturer to a developer of precision antibody immunotherapies.
“We started this turnaround story maybe two years ago by hiring the right team, bringing the right technology on board, and finally last year moving into our new space,” Martin Brenner, Ph.D. interim CEO and CSO, told GEN. “We are in the process and final steps to completely switch gears into a new biotech,” he said.
The backbone of the transition is iBio’s acquisition of RubrYc Therapeutics and its artificial intelligence drug discovery platform and iBio’s pipeline of immuno-oncology assets.
The GEN article can be accessed here.
